Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 8, 2019

View Archived Issues

Novel transgenerational mouse model of insulin resistance

Mycobiome linked to pancreatic cancer

Dual inhibition of TGF-beta and AXL as novel therapeutic approach in metastatic CRC

rSIFN-co demonstrates antitumor activity in phase I study in advanced solid tumors

Phase I results for DNA vaccine MVI-118 in patients with metastatic prostate cancer

C-75 improves survival of mice with sepsis through blocking TLR/MYD88 signaling in neutrophils

Enrollment underway in phase I/II study of CTNS-RD-04 stem cell gene therapy for cystinosis

First cohort subject dosed in phase I study of SCD inhibitor YTX-7739

NKTR-358 begins new phase Ib studies in psoriasis and atopic dermatitis

Inhaled AZD-8154 demonstrates superior pharmacokinetics over intravenous administration

Hawaii Biotech divulges compounds for anthrax

Biogen patents OGA inhibitors

H. Lee Moffitt Cancer Center and Research Institute presents YAP1/POU5F1 interaction inhibitors

Aerie Pharmaceuticals synthesizes new kinase inhibitors

Genentech patents TRPA1 antagonists

Dermavant initiates phase IIa study of cerdulatinib gel in vitiligo

Phase III extension study of VM-202 in diabetic peripheral neuropathy meets primary endpoint

BARDA contract supports Platelet BioGenesis' development of donor-independent platelets

Advaxis updates median overall survival data from phase I/II study of ADXS-PSA in metastatic CRPC

FDA approves Beovu for wet age-related macular degeneration

Evaluating gepotidacin in the treatment of uncomplicated urinary tract infections: a phase IIa study

Three win Nobel for hypoxia work

Bavarian Nordic begins first-in-human study of MVA-BN-WEV for equine encephalitis virus

ONL Therapeutics advances ONL-1204 into phase I study for retinal detachment

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 7, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 7, 2026.
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld Science
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
Science in 2025: the best of the rest
BioWorld Science
A review of 2025's noteworthy advances in medical research, including GLP-1 receptor agonists as anti-aging drugs, tumor-agnostic therapies and xenotransplants.
Development and characterization of anti-CD19 in vivo CAR T therapy
BioWorld Science
Shenzhen Grit Biotechnology Co. Ltd. and Shanghai Vitalgen Biopharma Co. Ltd. recently presented their work to develop and evaluate a novel anti-CD19 in vivo CAR...